Product Description
Artesunate injection is used to treat severe malaria. This medicine is also used together with other medicines (eg, 8-aminoquinoline medicine) to treat severe malaria caused by Plasmodium ovale or Plasmodium vivax. (Sourced from: https://www.mayoclinic.org/drugs-supplements/artesunate-intravenous-route/side-effects/drg-20489625?p=1)
Mechanisms of Action: NOTCH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | Belgium | Brazil | China | Colombia | Croatia | Czech | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | India | Indonesia | Ireland | Italy | Latvia | Lithuania | Malaysia | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Sweden | Thailand | Ukraine | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ministry of Health
Company Location:
Company Founding Year: 1947
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Bangladesh, Burkina Faso, Cambodia, Guinea, Kenya, Malaysia, Niger, Nigeria, Rwanda, Tanzania, United States, Unknown Location
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Malaria, Falciparum
Phase 2: Breast Cancer|Carcinoma in Situ|Cervical Cancer|Cervical Intraepithelial Neoplasia|Colorectal Cancer|Cytomegalovirus Infections|Friedreich Ataxia|Inflammation|Liver Cancer|Lung Cancer|Malaria|Nose Cancer|Obstetric Labor, Premature|Papilloma|Papillomavirus Infections|Prostate Cancer|Squamous Cell Carcinoma|Squamous Intraepithelial Lesions of the Cervix|Uterine Cancer|Uterine Cervical Dysplasia|Vaginal Cancer|Vulvar Cancer|Vulvar Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06853184 |
IVAS-CMV-01 | P2 |
Recruiting |
Cytomegalovirus Infections |
2028-05-31 |
12% |
2025-10-23 |
Primary Endpoints|Start Date |
NCT07095478 |
NeoART-CIN | P2 |
Not yet recruiting |
Lung Cancer|Breast Cancer|Inflammation|Prostate Cancer|Malaria|Obstetric Labor, Premature|Papilloma|Vaginal Cancer|Cervical Intraepithelial Neoplasia|Nose Cancer|Cervical Cancer|Liver Cancer|Colorectal Cancer |
2027-06-30 |
12% |
2025-08-01 |
Primary Endpoints|Treatments |
NCT03923725 |
DeTACT-Africa | P3 |
Completed |
Malaria, Falciparum |
2024-03-15 |
2025-11-19 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT05555862 |
anal HSIL HIV- | P2 |
Active, not recruiting |
Papillomavirus Infections|Squamous Cell Carcinoma|Carcinoma in Situ|Squamous Intraepithelial Lesions of the Cervix |
2026-12-28 |
12% |
2025-05-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06075264 |
ART-VIN IIB | P2 |
Recruiting |
Papillomavirus Infections|Vulvar Diseases|Vulvar Cancer |
2026-12-01 |
12% |
2025-08-15 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
NCT04098744 |
ART-CIN_IIB | P2 |
Recruiting |
Uterine Cancer|Cervical Cancer|Papillomavirus Infections|Uterine Cervical Dysplasia |
2026-07-31 |
12% |
2025-08-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2021-000171-36 |
2021-000171-36 | P2 |
Completed |
Friedreich Ataxia |
2024-04-17 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT03939104 |
DeTACT-ASIA | P3 |
Completed |
Malaria, Falciparum |
2023-01-06 |
2024-03-21 |
||
NCT07095309 |
NeoART-M | P2 |
Not yet recruiting |
Colorectal Cancer |
2032-08-30 |
12% |
2025-08-01 |
Primary Endpoints|Treatments |
NCT06206564 |
ART-AIN IIB-2 | P2 |
Recruiting |
Carcinoma in Situ|Papillomavirus Infections|Squamous Intraepithelial Lesions of the Cervix|Squamous Cell Carcinoma |
2026-12-31 |
12% |
2025-05-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06165614 |
LCCC2236 | P1 |
Completed |
Cervical Cancer|Uterine Cervical Dysplasia|Uterine Cancer |
2025-01-30 |
50% |
2025-08-20 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/06/2025 |
News Article |
Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025 |
|
07/22/2025 |
News Article |
Hesperos Demonstrates First Digital Twin of Human Disease Using Organ-on-a-Chip Platform |
|
06/30/2025 |
News Article |
Fosun International Garners Five Awards from Corporate Governance Asia |
|
06/11/2025 |
News Article |
Fosun International Receives the "ESG & Sustainability Award" and Two Other Prestigious Honors from Global Banking and Finance Review |